A physician recaps an academic panel session that discussed how the role of tirzepatide is changing in practice.
Recap by typeshit. Post by Facebook on Facebook.
The review looks at concerns about misuse as demand for GLP-1 drugs grows, and points to how little evidence guides their use beyond approved conditions.
Researchers found self-reported GLP-1 use climbed from March 2024 to October 2025, mostly for weight loss, through channels insurance data may not capture.
The study is looking for women with hot flashes and night sweats and a BMI above 30. Mayo Clinic has the full eligibility rules and how to sign up.
A matched cohort study in Inflammatory Bowel Diseases found remission odds nearly six times higher on GLP-1 drugs, and weight loss alone didn't explain it.
Survey data on 3,615 US adults showed about 30% lower odds of GLP-1 use among cancer survivors, despite more heart and kidney disease. Causes remain unclear.
A woman with bipolar disorder developed tremor and slurred speech three weeks into Zepbound. An outside expert advises checking lithium levels early, not avoiding the drugs.
Loading…